Bacterial Vaginosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bacterial Vaginosis – Drugs In Development, 2024 report and make more profitable business decisions.
Bacterial vaginosis (BV), also known as vaginal bacteriosis, is a type of vaginal inflammation caused by the overgrowth of bacteria present in the vagina. Symptoms include vaginal itching, burning during urination, and watery and thin vaginal discharge. Treatment includes antibiotics.
The Bacterial Vaginosis drugs in development market research report provide comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bacterial Vaginosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 29 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bacterial Vaginosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bacterial Vaginosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bacterial Vaginosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AtoGen Co LtdBiom Pharmaceutical Corp
BioNTech SE
CC Biotech Ltd
Chengdu Brilliant Pharmaceutical Co Ltd
Dare Bioscience Inc
Evofem Biosciences Inc
Ferring International Center SA
Guangdong Longchuangji Pharmaceutical Co Ltd
Jiangsu ProteLight Pharmaceutical & Biotechnology Co Ltd
LUCA Biologics Inc
Matrubials Inc
Melinta Therapeutics LLC
Mucommune LLC
MyBiotics Pharma Ltd
Next Science Ltd
Osel Inc
Pharmiva AB
Profem GmbH
Rutgers The State University of New Jersey
Seed Health Inc
Sichuan Anaerobic Biotechnology Co Ltd
Siolta Therapeutics Inc
Suzhou Kanger Biomedical Co Ltd
Suzhou Ousai Weike Biomedical Technology Co Ltd
TenNor Therapeutics Ltd
Toltec Pharmaceuticals LLC
Zhejiang Xinlifei Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bacterial Vaginosis reports